BrainStorm Cell receives notice from EPO to grant patent BrainStorm Cell Therapeutics announced that it has received notification from the European Patent Office of its intention to grant the company’s patent application No. EP06766101.7. This patent relates to the method of production of the company's proprietary stem cells induced to secrete large quantities of neurotrophic factors for the treatment of neurodegenerative diseases. The company's proprietary NurOwn stem cell therapy was developed from this differentiation method.
Piper Jaffray and the Alliance for Regenerative Medicine co-host conference 3rd Annual Regenerative Medicine Investor Day is being held in New York on March 25 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link